Understanding the mechanism of cisplatin nephrotoxicity could lead to novel renoprotective interventions.
CISPLATIN NEPHROTOXICITY
Nephrotoxicity was reported in the initial clinical trials of cisplatin chemotherapy. 17 Now, it is recognized that the prevalence of cisplatin nephrotoxicity is high, occurring in about one-third of patient undergoing cisplatin treatment. 4, 18 Clinically, cisplatin nephrotoxicity is often seen after 10 days of cisplatin administration and is manifested as lower glomerular filtration rate, higher serum creatinine, and reduced serum magnesium and potassium levels. 4, 19, 20 On the other hand, the long-term effects of cisplatin on renal function are not completely understood, but it is believed that cisplatin treatment may lead to subclinical but permanent reduction in glomerular filtration rate. 21 The pathophysiological basis of cisplatin nephrotoxicity has been studied for the last three decades. However, only recently has the research been directed toward the understanding of the cellular and molecular mechanism. The emerging picture ( Figure 1 ) is that the exposure of tubular cells to cisplatin activates complex signaling pathways that lead to tubular cell injury and death. Meanwhile, a robust inflammatory response is stimulated, further exacerbating renal tissue damage. Cisplatin may also induce injury in renal vasculature and result in decreased blood flow and ischemic injury of the kidneys, contributing to a decline in glomerular filtration rate. These events, together, culminate in the loss of renal function during cisplatin nephrotoxicity, triggering acute renal failure. Apparently, this is a simplistic view and as discussed in the following sections, cisplatin nephrotoxicity is now recognized as a very complex multifactorial process.
CISPLATIN UPTAKE AND METABOLISM
The mechanism of intracellular transport of cisplatin is not clear and may vary from one cell type to another. Earlier work using cancer cell lines concluded that about half of the cisplatin uptake is due to passive diffusion through the plasma membrane, and the remaining half is mediated by an unknown transporter. 22 In 2002, Ishida et al. 23 showed that deletion of the Ctr1, a high-affinity copper transporter, results in reduced intracellular accumulation of cisplatin in yeast, which is associated by increased resistance to cisplatin toxicity. Similar observations were shown in mouse cell lines lacking one or both mouse Ctr1 (mCtr1) alleles, suggesting that copper transporters may mediate cisplatin uptake in both yeast and mammals. In addition, ATP7B, a copper efflux transporter, has been shown to be overexpressed in cancer cell lines that are resistant to cisplatin. 24, 25 Together, these studies, mainly from cancer cells, have suggested a critical role for the copper transport system in cisplatin uptake by cells. It is interesting to note that Ctr1 is also highly expressed in proximal tubular cells, 26 although the role of these transporters in cisplatin uptake has not been studied in renal models.
On the other hand, in the renal system, the organic cation transporters (OCTs) have been implicated in cisplatin uptake. 27, 28 OCTs mediate the basolateral-to-apical transport of several cationic compounds in renal tubular cells. In 2004, Ludwig et al. 27 showed that cisplatin, when applied at the basolateral side, induced higher toxicity in MDCK cells than apical side application. The results suggest that cisplatininduced tubular cell injury may be related to basolateral organic cation transport. Notably, cimetidine, an inhibitor of OCTs, could partially prevent cisplatin-induced cytotoxicity shown by the decrease of transepithelial electrical resistance. 27 Three isoforms of OCTs are expressed in renal proximal tubules, mainly at the basolateral side. 29 Recent work by Ciarimboli et al. 30 provided evidence to suggest that OCT2 is the critical OCT responsible for cisplatin uptake in the kidney. They showed that cisplatin uptake was increased by OCT2 overexpression in HEK293 cells, which was associated with increased cellular sensitivity to cisplatin toxicity. Consistently, cimetidine decreased cisplatin uptake in freshly isolated human proximal tubular cells. In addition, proximal tubular cells isolated from a human diabetic kidney showed reduced cisplatin uptake, which was attributed to the well-documented lower expression of OCT2 in diabetes. Interestingly, cisplatin did not interact with OCT1. It was speculated that since OCT1 is mainly expressed in the liver and OCT2 in the kidneys, this differential expression pattern of OCTs in different tissues might account for organ-specific toxicity of cisplatin. Of note, the less nephrotoxic analogues of cisplatin such as carboplatin and oxaliplatin did not interact with OCT2. 30 After entry into the cell, cisplatin may interact with various kinds of reactive groups. In the kidney, it has been suggested that the nephrotoxicity of cisplatin may depend on metabolic activation, which involves a pathway including g-glutamyl transpeptidase and cysteine-S-conjugate b-lyase. 31 Inhibition of either of the enzymes led to amelioration of cisplatin nephrotoxicity in mice. 32, 33 Notably, prostate cancer xenografts overexpressing g-glutamyl transpeptidase were more resistant to cisplatin therapy, suggesting that inhibition of the cisplatin activation pathway may reduce the nephrotoxicity of cisplatin, yet enhance its antitumor effect. 34 Further investigation is needed to directly test this possibility and determine whether the bioactivation is indeed critical to cisplatin nephrotoxicity.
Cisplatin

CELL DEATH IN CISPLATIN NEPHROTOXICITY: TYPES AND LOCATIONS
Renal tissue damage, characterized by tubular cell death, is a common histopathological feature of cisplatin nephrotoxicity. Under this condition, cell death in the form of both necrosis and apoptosis is identified. Recent studies have provided new insights into the possible connections between these two forms of cell death. In addition, the cell types that undergo apoptosis during cisplatin nephrotoxicity have been further investigated.
Using cultured renal tubular cells, earlier observations by Lieberthal et al. 35 suggested that the dosage of cisplatin might determine whether the cells die by necrosis or apoptosis. Necrotic cell death was observed when a high concentration of cisplatin (millimolar) was used, while lower concentrations of cisplatin (micromolar) led to apoptosis. Nevertheless, in vivo in animals, both necrosis and apoptosis were induced in renal tubules following cisplatin administration. [36] [37] [38] Is there a relationship between necrosis and apoptosis in the injured tissues? Necrosis can be induced directly by severe toxic injury. However, it can also be a postmortem result of apoptosis, termed secondary necrosis. In addition, despite their distinct morphologies, necrosis and apoptosis may share some important signaling events. For example, mitochondrial damage by proapoptotic proteins such as Bid and Bax could destine the cells to death. Under this condition, if downstream apoptotic events are defective or aborted, the cells will become passive and finally end up being lysed in the form of necrosis. Although in vivo evidence to support this scenario is lacking, renoprotective agents frequently prevent both necrosis and apoptosis in renal tissues during cisplatin nephrotoxicity. [39] [40] [41] Moreover, knockout of known apoptotic genes such as Bax diminishes tubular cell apoptosis as well as necrosis under this condition. 42 It is well recognized that renal tubules are the major sites of cell injury and death during cisplatin nephrotoxicity. Earlier work suggested that the distal tubules were the primary site of apoptosis. 36 However, recent studies indicated that proximal tubular cells also undergo apoptosis during cisplatin nephrotoxicity. 41, 43 Nevertheless, these studies did not clearly identify the cell type(s) of apoptosis using specific markers. A more recent study has addressed this question by using proximal and distal tubule-specific lectins. It was shown that many apoptotic cells were stained by phytohemagglutinin, a proximal tubule-binding lectin, whereas significantly fewer apoptotic cells were stained by peanut lectin agglutinin, a distal tubule-binding lectin. 42 Thus, apoptosis occurs in both tubular segments, but the majority is in proximal tubules. These observations justify the extensive use of primary as well as immortalized proximal tubular cells for mechanistic studies of cisplatin nephrotoxicity. Interestingly, cisplatin can also induce necrosis and apoptosis in cultured endothelial cells, although evidence is yet to be demonstrated for endothelial cell apoptosis during cisplatin nephrotoxicity in vivo. 44 
APOPTOTIC PATHWAYS IN CISPLATIN NEPHROTOXICITY
During the last few years, apoptosis of renal tubular cells has been a focus of mechanistic investigation of cisplatin nephrotoxicity. Several pathways of apoptosis have been implicated, including the extrinsic pathway mediated by death receptors, the intrinsic pathway centered on mitochondria, and the endoplasmic reticulum (ER)-stress pathway ( Figure 2 ).
In the extrinsic pathway, binding of the death receptors by ligands at the plasma membrane leads to the recruitment and activation of caspase-8, which further activate downstream caspases to induce apoptosis. 45 Major death receptors include Fas, tumor-necrosis factor-a (TNF-a) receptor (TNFR) 1 and 2. In cultured human proximal tubular cells, Razzaque et al. 46 showed an upregulation of Fas and Fas ligand by cisplatin, which was associated with apoptosis. However, definitive In addition, ER stress may also be induced (gray). Activation of these pathways leads to caspase-dependent or -independent apoptosis.
evidence for a role of Fas in cisplatin-induced tubular cell apoptosis was not established. On the other hand, Tsuruya et al. 43 demonstrated the amelioration of cisplatin-induced tubular cell apoptosis and renal failure in TNFR1-deficient cells and mice, suggesting the involvement of TNFR1 signaling in cisplatin nephrotoxicity. In 2002, Ramesh and Reeves 47 demonstrated an impressive induction of TNF-a by cisplatin in mice. Importantly, pharmacological and genetic inhibition of TNF-a attenuated the production of various cytokines and chemokines, which was accompanied by the amelioration of cisplatin nephrotoxicity. A follow-up study by these investigators further showed that TNFR2-deficient, but not TNFR1-deficient, mice were resistant to cisplatininduced renal injury. 37 While these studies support a role for TNF-a in the inflammatory response and cisplatin nephrotoxicity, it is suggested that TNFR2, and not TNFR1, is mainly responsible for the pathogenic signaling of TNF-a. 37 Of note, TNF-a and its receptors may induce renal injury primarily by mounting a disastrous inflammatory response rather than by directly activating the extrinsic pathway of apoptosis. 48 On the other hand, the intrinsic or mitochondrial pathway has emerged as the major apoptotic pathway in cisplatin nephrotoxicity. In the intrinsic pathway, cellular stress leads to the activation of the proapoptotic Bcl-2 family proteins Bax and Bak, which form porous defects on the outer membrane of mitochondria, resulting in the release of apoptogenic factors from the organelles. 45, 49, 50 The apoptogenic factors released from mitochondria include cytochrome c, AIF (apoptosis-inducing factor), Smac/DIABLO, endonuclease G, and others. Cytochrome c, after being released into the cytosol, binds to and induces conformational changes in the adaptor protein Apaf-1, leading to the recruitment and activation of caspase-9, which in turn after proteolytic processing activates downstream caspases for caspase-dependent apoptosis. Smac, after being released into cytosol, can bind and antagonize the caspase inhibitor proteins, IAPs (inhibitor of apoptosis proteins) to further augment caspase activation. In contrast, AIF, after being released from mitochondria, accumulates in the nucleus to induce apoptosis in a caspase-independent manner. The involvement of the intrinsic pathway of apoptosis in cisplatin-induced renal injury was initially suggested by Bax accumulation in mitochondria and cytochrome c release in cultured kidney cells. 51 Using renal epithelial cells, Lee et al. 51 and Park et al. 52 provided the first evidence for Bax activation following cisplatin treatment, which was accompanied by mitochondrial release of cytochrome c, activation of caspase-9, and apoptosis. These initial observations were confirmed by several other studies using different cell lines. [53] [54] [55] [56] In addition, cisplatin induced the release of AIF from mitochondria in LLC-PK1 cells. 57 Importantly, blockade of Bax by expressing Bcl-2 diminishes mitochondrial injury and cisplatin-induced apoptosis. 53, 54 Moreover, several pharmacological agents with demonstrated antiapoptotic effects can attenuate Bax activation and accumulation in mitochondria, resulting in prevention of cytochrome c release, inhibition of caspase activation, and amelioration of apoptosis. 53, 54, 56, [58] [59] [60] Our recent work has further demonstrated compelling evidence for tubular apoptosis via the intrinsic pathway during cisplatin nephrotoxicity using Bax-deficient mouse models. 42 In wild-type (WT) C57BL/6 mice, cisplatin induced Bax in renal tubular cells, which became active, accumulated in mitochondria, and was accompanied by acute kidney injury. Notably, when Bax was genetically deleted, the animals became resistant to cisplatin. Baxdeficient mice demonstrated less cytochrome c release and lower tubular apoptosis. Proximal tubular cells isolated from these animals were also resistant to cisplatin-induced apoptosis. 42 While a central role for the intrinsic or mitochondrial pathway of apoptosis in cisplatin nephrotoxicity has been established, the molecular mechanism underlying mitochondrial injury is largely unclear. Specifically, it is unknown how Bax is activated under the pathological condition. It is generally believed that Bax activation is related to a shift of the balance between the pro-and antiapoptotic Bcl-2 proteins to the proapoptotic direction. In cultured tubular cells, cisplatin treatment leads to the decrease or degradation of the antiapoptotic proteins including Bcl-2, Bcl-XL, and Mcl-1, 54, 61 whereas the proapoptotic proteins such as Bax and Bak are not changed or even increased. In vivo, the ratio between Bax and Bcl-2 is elevated during cisplatin nephrotoxicity. 42, 62 These changes of apoptotic gene expression are expected to favor the activation of Bax (and probably Bak as well) to trigger mitochondrial injury and apoptosis. In addition, cisplatin treatment can induce the expression of proapoptotic BH3 domain only proteins. One such example is PUMA-a (p53-upregulated modulator of apoptosis), which is induced in a p53-dependent fashion during cisplatin nephrotoxicity. 54 The induced PUMA-a accumulates in mitochondria, where it interacts with and neutralizes the antiapoptotic protein Bcl-XL, freeing Bax to form pores on the outer membrane of mitochondria. 54 Moreover, our recent work has revealed a striking morphological change of mitochondria during cisplatin injury, from filamentous shape to punctate fragments. 63 Blocking the morphological change can abrogate mitochondrial injury and prevent cisplatininduced apoptosis, suggesting an important role for the regulation of mitochondrial morphological dynamics in cisplatin injury. 63 How does the morphological change affect mitochondrial membrane integrity during apoptosis? Does it contribute to Bax/Bak activation? These are the immediate questions to be addressed.
In addition to the extrinsic and intrinsic pathways, tubular cell apoptosis following cisplatin treatment may also involve the ER-stress pathway. The initiator caspase in the ER pathway is caspase-12, which is localized at the cytosolic face of the ER and is activated by ER stress. 64 Liu and Baliga 65 showed that caspase-12 was activated during cisplatin treatment of LLC-PK1 cells, and, interestingly, transfection of an anticaspase-12 antibody attenuated apoptosis in this model. The in vitro observations were recently extended to a rat model of cisplatin nephrotoxicity, where ER stress and related signaling such as caspase-12 cleavage were demonstrated. 66 Another ER-associated protein that has been implicated in cisplatin injury is a Ca 2 þ -independent phospholipase A 2 (ER-iPLA 2 ). Cummings et al. 67 showed that pharmacological inhibition of ER-iPLA 2 led to amelioration of cisplatin-induced apoptosis in primary rabbit proximal tubular cultures. ER-iPLA 2 may act downstream of p53 and upstream of caspase-3 in the apoptotic pathway. Despite these observations, the regulation of ER stress, and, importantly, its role in cisplatin nephrotoxicity remains to be established.
Finally, it is important to recognize that although the classical apoptotic pathways involving caspases play critical roles in cisplatin nephrotoxicity, not all the apoptosis is mediated by caspases. In immortalized as well as primary tubular cells, a significant portion of apoptosis cannot be inhibited by VAD (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone), a broad-spectrum peptide inhibitor of caspases. 53, 68 The mechanism of caspaseindependent apoptosis is currently unclear, but may involve AIF. In addition, autophagic cell death occurs independent of caspases. 69, 70 Whether cisplatin induces autophagy and whether autophagy is involved in cisplatin-induced cell death is an interesting area for future investigation.
p21 AND CELL-CYCLE REGULATION IN CISPLATIN NEPHROTOXICITY
Cell-cycle proteins have emerged as major molecular regulators of renal cell death and protection during cisplatin nephrotoxicity. 71 Normally, the cell cycle is regulated by members of the cyclin-dependent kinase (cdk) family and their specific regulatory proteins called cyclins. Specific cdk/ cyclin complexes regulate major transitions during cell cycle, such as entry from quiescence, commitment to DNA synthesis, and finally the transition from G2 to mitosis. Because of their critical roles, cdks are negatively regulated by two classes of inhibitors: the INK4 and CIP/KIP family of cdk inhibitors. [72] [73] [74] The role of cdks and cdk inhibitors, especially p21, in cisplatin nephrotoxicity has been demonstrated by Price, Safirstein, and their colleagues 36, [75] [76] [77] [78] [79] in a series of studies. Thus, the balance between cdks and p21 is an important factor, which determines whether the renal tubular cells survive or undergo cell death ( Figure 3 ). It is clear now that during cisplatin nephrotoxicity, the quiescent renal cells enter cell cycle as shown by PCNA (proliferating cell nuclear antigen) staining and BrdU incorporation in nucleus. 36 But at the same time the expression of p21, a cdk inhibitor of the CIP/KIP family, is also induced. p21 is induced during cisplatin nephrotoxicity via p53-dependent as well as p53-independent mechanisms. 75 Notably, p21-null mice are highly sensitive to cisplatin-induced acute renal failure. 36 Compared with WT animals, p21-null mice showed a more rapid onset of acute renal failure following cisplatin administration. Consistently, morphological examination of renal tissues showed severe tissue damage and tubular cell apoptosis in the p21-null mice. Importantly, these mice showed higher mortality than their WT littermates. These observations suggest that p21 induction during cisplatin nephrotoxicity is a renoprotective response. This inference is further supported by the cytoprotective effects of p21 overexpression in mouse proximal tubular cells. On the other hand, pharmacological inhibitors of cell cycle did not afford general cytoprotective effects, suggesting that p21 per se, rather than the associated cell-cycle inhibition, is the key to cytoprotection during cisplatin nephrotoxicity. 76 The p21 protein has several functional domains, which can interact with various proteins including cyclin, cdk, caspase-3, PCNA, and c-Myc, to name a few. Using serial deletion mutants, Yu et al. 77 have recently determined the critical structural domains in p21 that are responsible for its cytoprotective action. This analysis narrowed the cytoprotective domain down to amino acid 38-91 at the NH 2 terminus of p21, which contains the cdk2-binding domain. Indeed, cdk2 was activated during cisplatin incubation and the activation was attenuated by p21. Moreover, inhibition of cdk2 by dominant-negative mutants protected tubular cells from cisplatin-induced apoptosis. 77 These observations suggest that cdk2 may be an important cell killing molecule during cisplatin nephrotoxicity and a key target of p21. This conclusion is further supported by recent data showing the protective effects of cdk2 inhibitors in tubular cell cultures and in vivo in 129/Sv mice. 78, 79 In addition, cdk2-null mouse embryonic fibroblasts were shown to be resistant to cisplatininduced apoptosis and the sensitivity could be restored by cdk2 transfection. 78, 79 Of note, these studies further identified E2F1 as an important downstream effector of cdk2. 79 Together, these observations have demonstrated compelling evidence for a role of cdk2 in cisplatin nephrotoxicity. p21 may protect renal cells from apoptosis by inhibiting cdk2.
p53 SIGNALING IN CISPLATIN NEPHROTOXICITY
The involvement of p53, the well-recognized tumor suppressor protein, in cisplatin nephrotoxicity was first suggested by Cummings and Schnellmann. 68 It was shown that pifithrin-a, a pharmacological inhibitor of p53, could partially suppress cisplatin-induced apoptosis in rabbit proximal tubular cells. 68 We confirmed the inhibitory effects of pifithrin-a in rat proximal tubular cells and further demonstrated the inhibitory effects of dominant-negative p53. 53 Since the dominant-negative mutant had a point mutation in the DNA-binding site of p53, it was suggested that the proapoptotic action of p53 may be related to its transcriptional activity. 53 Consistently, p53 was rapidly phosphorylated and induced during cisplatin incubation, prior to tubular cell apoptosis. The role of p53 in cisplatin nephrotoxicity is further supported by our recent in vivo experiments, which showed p53 activation in renal tubular cells, partially colocalizing with apoptosis. Importantly, tubular cell apoptosis, renal tissue damage, and cisplatininduced renal failure were ameliorated in p53-deficient mice and by pifithrin-a in WT animals. 80 Mechanistically, PUMA-a, a proapoptotic Bcl-2 family protein, was identified as a major downstream mediator of the killing action of p53. 54 PUMA-a was drastically induced by cisplatin both in vitro in cultured proximal tubular cells and in vivo in kidneys, and this induction was dependent on p53. Upon induction, PUMA-a accumulated in mitochondria, where it interacted with and presumably neutralized Bcl-XL, freeing Bax to permeabilize the mitochondrial membrane to release apoptotic factors such as cytochrome c (Figure 4) . Consistently, cisplatin-induced apoptosis was ameliorated in PUMA-a knockout cells. 54 In addition to PUMA-a, Seth et al. 57 suggested that PIDD (p53-induced protein with death domain) might be another proapoptotic gene that mediates cisplatin-induced apoptosis downstream of p53. PIDD was shown to be induced by cisplatin in primary mouse renal tubular cells in a p53-dependent manner. Following induction, PIDD might activate caspase-2 to induce AIF release from mitochondria 57 (Figure 4 ). It is noteworthy that, in addition to gene transcription, p53 may also induce apoptosis by directly activating proapoptotic Bcl-2 family proteins, leading to mitochondrial injury and the release of apoptogenic factors. 81 Whether the direct mechanism is involved in cisplatin-induced renal tubular cell death is unknown.
How is p53 activated during cisplatin nephrotoxicity? We do not have a clear answer yet. Nevertheless, it is generally believed that p53 activation by cisplatin may be triggered by DNA damage or genotoxic stress. After entering the cell, cisplatin is aquated into a highly reactive form (Figure 2 ), which can bind to and induce modification of various kinds of molecules. Among these molecular targets, cisplatin is believed to cross-link genomic DNA. Cross-linking of DNA leads to distortion of the duplex structure and stalling of the replication fork, inducing genotoxic stress. Under this condition, forced DNA synthesis further leads to single-as well as double-strand breaks. In cancer cells and tumors, genotoxic stress and DNA damage are recognized as a major cellular response to cisplatin and are considered to be a critical event for its therapeutic effects. 2, 3, 5 In addition, the activation of DNA repair mechanisms has been implicated in cisplatin resistance in malignant cells. 2 damage and repair response during cisplatin nephrotoxicity is scarce. Nevertheless, a recent study by Zhou et al. 82 indicates that proteins related to cell-cycle regulation and DNA repair, such as cdk inhibitors (p21 and p27), cyclin B1, cyclin D1, PCNA, GADD 45, and GADD 153, are induced by cisplatin in kidney cells. In addition, enhanced expression of DNA repair genes is associated with the amelioration of cisplatin injury, further suggesting that DNA damage may contributes to cisplatin nephrotoxicity. 82 It remains unclear as to what is the sensor of cisplatin-induced DNA damage and which proteins relays the DNA damage signal to p53, resulting in cell injury and death in kidneys. To gain insights into this question, our recent work has examined ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia and Rad-3-related), two major molecular 'sensors' of genotoxic stress and DNA damage. ATM was shown to be proteolytically cleaved and inactivated during late stage of cisplatin treatment in renal tubular cells. 83 In sharp contrast, ATR was activated early following cisplatin exposure and, notably, suppression of ATR could attenuate cisplatininduced p53 activation and apoptosis 84 (Figure 4 ). Further investigation of DNA damage response in normal and cancer cells may identify critical differences, which can be targeted for renoprotection during cisplatin chemotherapy. It is important to note that although, DNA damage is considered one of the most important mechanisms of cisplatin-induced cytotoxicity, targeting of other molecules and structures may also contribute. For example, cisplatin has been reported to interact and disrupt the function of Hsp 85 contributing to cisplatin nephrotoxicity. 86 
MAPK ACTIVATION IN CISPLATIN NEPHROTOXICITY
The MAPK (mitogen-activated protein kinase)-signaling pathways consist of several tiers of highly conserved serine/ threonine protein kinases, which result in terminal activation of ERK (extracellular signal-regulated kinase), p38 and JNK (Jun N-terminal kinase) or SAPK (stress-activated protein kinase). 87, 88 Activation of MAPKs regulates cellular homeostasis and processes including proliferation, differentiation, and apoptosis. 87, 88 ERK, p38, and JNK/SAPK are activated in various experimental models of cisplatin nephrotoxicity. However, the roles played by specific MAPKs in cisplatininduced renal cell injury appear to be very complicated, vary between different studies, and may depend on the cell types and experimental models to be examined. Of the eight known ERK isoforms, ERK1 and ERK2 are ubiquitously expressed and most widely studied. [87] [88] [89] These two ERKs are activated following phosphorylation by MEK (MAPK/ERK kinase) 1 and MEK2. In 2002, Nowak 90 showed that ERK1/2 were activated and accumulated in mitochondria during cisplatin treatment of primary cultures of renal tubular cells. Inhibition of ERK1/2 with PD98059 and U0126, two pharmacological MEK inhibitors, could ameliorate cisplatin-induced mitochondrial dysfunction and apoptosis. Interestingly, PD98059 and U0126 did not prevent cytochrome c release from mitochondria, yet inhibited caspase activation, suggesting a downstream inhibitory effect. The cytoprotective effect of PD98059 and U0126 have been confirmed and extended to immortalized renal tubular cell lines, 91, 92 although there is evidence that these inhibitors may also block upstream apoptotic events including Bax activation and cytochrome c release. 92 Notably, in addition to pharmacological inhibitors, the latter studies also used molecular approaches to decipher the role of ERK in cisplatin nephrotoxicity. It was shown that transient transfection of constitutively active MEK1 resulted in increased apoptosis, whereas dominant-negative MEK1 decreased cisplatin-induced apoptosis in renal tubular cells. 92 Importantly, the study by Arany et al. 91 further identified EGFRdependent Src kinase activation as a key upstream event for ERK1/2 activation. In vivo, cisplatin induced an early ERK, p38, and JNK/SAPK activation, which preceded the development of acute renal injury and renal failure. 91 A role for ERK activation in cisplatin nephrotoxicity in vivo was recently verified by Won et al. 93 using U0126.
As compared with ERK, the roles played by p38 and JNK/ SAPK in cisplatin nephrotoxicity are less clear. In immortalized mouse proximal tubule cells, although all three MAPKs were activated by cisplatin, only ERK was shown to contribute to apoptosis. 91 In contrast to these results, Ramesh et al. 40 demonstrated a role for p38 in cisplatin nephrotoxicity using both in vitro and in vivo models. Specifically, pharmacological inhibitors of p38 (that is, SB203580 and SKF-86002) were shown to be renoprotective in these models. These results were confirmed recently by Mishima et al. 94 Interestingly, instead of directly regulating tubular cell injury and death, p38 may regulate TNF-a expression in renal tubular cells and consequent inflammatory response during cisplatin nephrotoxicity. 40, 94 Jun N-terminal kinase/stress-activated protein kinase activation by cisplatin was shown in cultured renal tubular cells as well as kidney tissues. 91, 95 However, evidence for a role of JNK/SAPK in cisplatin-induced nephrotoxicity were not reported until very recently. Using an in vivo rat model, Francescato et al. 95 showed that treatment with the JNK inhibitor SP600125 could reduce renal apoptosis and inflammation during cisplatin nephrotoxicity. In light of the results (sometimes contrasting) reported by different groups, it is important to analyze ERK, p38, and JNK/SAPK all together in the same samples and systematically characterize their temporal and spatial activation during cisplatin treatment. 91 Also, the use of pharmacological inhibitors should be justified by vigorous examination of their specificity.
OXIDATIVE STRESS
For over a decade, oxidative stress has been recognized as an important factor that contributes to cisplatin nephrotoxicity. 96 Increases of various reactive oxygen species (ROS) occur during cisplatin treatment of cultured renal tubular cells, kidney slices, and in vivo in whole animals. Three mechanisms have been proposed to account for ROS generation under these pathological conditions. First, once in a cell, cisplatin is aquated into a highly reactive form, which can rapidly react with thiol-containing molecules including glutathinone, a well-recognized cellular antioxidant. 4, 5 Depletion or inactivation of glutathione and related antioxidants by cisplatin is expected to shift the cellular redox status, leading to the accumulation of endogenous ROS and oxidative stress within the cells. Second, cisplatin may induce mitochondrial dysfunction and increase ROS production via the disrupted respiratory chain. For example, in porcine proximal tubular cells, cisplatin treatment for 20 min reduced the activity of mitochondrial respiration complexes I-IV by 15-55%, resulting in ROS generation. 97 Paradoxically, ROS formation under this situation was dependent on residual electron flow through the mitochondrial respiratory chain, because complete inhibition of the respiration complexes blocked ROS accumulation. 97 The role of mitochondrial production of ROS in cisplatin-induced renal injury was further indicated by the cytoprotective effects of mitochondria-localized manganese superoxide dismutase. 98 Interestingly, in the same study, expression of catalase in mitochondria did not have significant protective effects, suggesting that superoxide (and not hydrogen peroxide) may be the major injurious oxidant species generated by mitochondria. In contrast, it was shown recently that catalase and its derivatives not only ameliorate cisplatin-induced nephrotoxicity but also improve the efficiency of cisplatin to treat solid tumors. 99 Finally, cisplatin may induce ROS formation in the microsomes via the cytochrome P450 (CYP) system. Using both in vitro and in vivo models, Baliga and colleagues 38, 96, 100, 101 showed that CYP was an important source of catalytic iron for ROS generation during cisplatin treatment. In CYP2E1-null mice, cisplatin-induced ROS accumulation was attenuated, so was renal injury. 38 Despite the recognition of a role for oxidative stress in cisplatin nephrotoxicity, the critical molecular targets of ROS in renal tubular cells remain largely unknown. By their broad reactive nature, ROS may target and modify multiple molecules in the cells such as lipids, proteins, and DNA, resulting in cellular stress. Notably, ROS appear to be involved in the activation of several important signaling pathways during cisplatin nephrotoxicity. For example, Ramesh and Reeves 40 showed that p38 activation in renal tissues following cisplatin treatment was abolished by dimethylthiourea (DMTU), a hydroxyl radical scavenging chemical, which was accompanied by the amelioration of inflammation and renal injury. Consistently, we showed recently that hydroxyl radicals were rapidly produced during cisplatin incubation of renal tubular cells. 59 DMTU and the general antioxidant N-acetylcysteine suppressed hydroxyl radical accumulation, p53 activation, and cisplatin nephrotoxicity in cultured tubular cells and in vivo in C57BL/6 mice. 59 These observations suggest that ROS may be one of the early signals that are at least partially responsible for the activation of various signaling pathways to culminate in renal cell injury and death during cisplatin nephrotoxicity.
In addition to injury, renal cells may also mount a cytoprotective response under oxidative stress. This is best illustrated by the investigation of heme oxygenase-1 or HO-1. 102-104 HO-1 is a redox-sensitive microsomal enzyme that catalyzes the degradation of heme into biliverdin, iron, and carbon monoxide. 105 The early induction and cryoprotective role of HO-1 during cisplatin-induced acute kidney injury was first suggested by Agarwal et al. 102 Later studies showed that the HO-1-deficient mice were significantly more sensitive to cisplatin-induced renal injury as compared with their WT littermates. 103 Moreover, in an in vitro model, overexpression of HO-1 significantly ameliorated cisplatininduced apoptosis. 103 The molecular basis of cryoprotective effects of HO-1 is not entirely clear. But the mechanisms that have been postulated are degradation of the prooxidant heme moiety, generation of antioxidant bilirubin, and generation of cryoprotectant carbon monoxide. 105 Indeed, a recent study has shown that carbon monoxide can significantly ameliorate cisplatin-induced renal injury in vitro and in vivo. 106 Further research involving the role of HO-1 and its downstream products may not only provide the mechanistic understanding of cisplatin-induced renal injury, but may also lead to identification of better renoprotective agents.
In various experimental models, renoprotective effects have been demonstrated for antioxidants including DMTU, melatonin, selenium, vitamin E, N-acetylcysteine, and many others. 40, 59, [107] [108] [109] [110] [111] [112] However, whether these antioxidant chemicals are renoprotective in human patients during cisplatinbased chemotherapy is uncertain. In a clinical trial conducted in 48 Dutch cancer patients, the test group had a dietary supplement consisting of vitamin C, vitamin E, and selenium; no significant differences were shown between the test and the placebo groups in terms of severity of renal injury induced by cisplatin. 113 In contrast, another study conducted in 1999 showed that oral supplementation of vitamin E was effective in decreasing the incidence and severity of cisplatin-induced peripheral neurotoxicity and nephrotoxicity. 114 Patient compliance and the dosage of antioxidant supplements may be key determinants of the trial outcome. Of note, in addition to the tested chemicals, antioxidant agents extracted from natural products have attracted recent interest. [115] [116] [117] [118] [119] Importantly, the natural product antioxidants may detoxify ROS in kidneys, without affecting the anticancer efficacy of cisplatin. Although the active ingredients are not known for all these natural products but if the renoprotective effects are proven true in humans, these antioxidants could have potential therapeutic applications.
INFLAMMATION
Acute kidney injury is associated with a robust inflammatory response. 48, [120] [121] [122] In the case of cisplatin nephrotoxicity, a myriad of proinflammatory cytokines and chemokines are induced. Importantly, inflammation contributes to the development of renal tissue damage and renal failure under the pathological condition. This inference was initially suggested by Deng et al., 123 who showed that the antiinflammatory cytokine IL-10 could ameliorate cisplatininduced renal tissue injury and tubular cell death. The role of the inflammatory response in cisplatin nephrotoxicity has been further established by studies that target specific inflammatory factors such as TNF-a, using pharmacological as well as genetic approaches. 37, 47, 48, 124 In the inflammatory response triggered by cisplatin, TNF-a appears to be a key upstream regulator. Ramesh and Reeves 47 showed that pharmacological inhibitors and antibodies against TNF-a markedly suppressed the induction of other cytokines during cisplatin nephrotoxicity. Similar inhibitory effects were shown in TNF-a-deficient mice. Importantly, inhibition of TNF-a was associated by the amelioration of cisplatin nephrotoxicity. 47 These observations have been verified and extended by other studies. [125] [126] [127] [128] Together, these studies have demonstrated a critical role for TNF-a in mounting the proinflammatory response during cisplatin nephrotoxicity and the ensuing kidney injury and acute renal failure.
How does TNF-a stimulate the inflammatory response and contribute to cisplatin nephrotoxicity? As a pleiotropic cytokine, TNF-a may engage the cell surface receptors TNFR1 and TNFR2 to induce a variety of cellular responses, ranging from inflammation to cell death. Tsuruya et al. 43 showed that, compared with WT, TNFR1-deficient mice and renal tubular cells were more resistant to cisplatin-induced injury and apoptosis, suggesting an important role for TNFa/TNFR1 signaling in tubular cell apoptosis under the experimental conditions. In sharp contrast, Ramesh and Reeves 37 demonstrated that TNFR1-deficient mice were as sensitive to cisplatin injury as the WT; however, TNFR2deficient mice were more resistant to cisplatin-induced tubular cell death and renal injury. Although the cause of the discrepancy between these two studies is not clear, both suggested a critical role for TNF-a signaling in cisplatin nephrotoxicity. Subsequent studies by Reeves and colleagues 40, [125] [126] [127] have demonstrated that TNF-a is critical to the induction of proinflammatory factors and recruitment of inflammatory cells.
Recent research has gained significant insights into the mechanism underlying TNF-a induction during cisplatin nephrotoxicity. 128 Particularly, a role for renal tubular cells has been suggested. First, the latest work by Reeves and colleagues 127 indicates that TNF-a is produced during cisplatin nephrotoxicity mainly by resident kidney cells, and not by infiltrating inflammatory cells. In this study, chimeric mouse models were created, in which bone marrow of recipient animals was ablated and then reconstituted with bone marrow derived from WT or TNF knockout donor mice. It was shown that cisplatin induced TNF-a, inflammation, and renal injury in WT recipients but not in TNFdeficient recipients, no matter what bone marrow was reconstituted. Second, emerging evidence has demonstrated that cisplatin induces TNF-a production in proximal tubular cells via gene transcription and mRNA stabilization. Notably, in the presence of endotoxins, TNF-a induction by cisplatin is dramatically increased. 129 These findings suggest that renal tubular cells contribute significantly to TNF-a production during cisplatin nephrotoxicity and related pathological conditions.
While parenchymal kidney cells have been implicated in TNF-a production during cisplatin nephrotoxicity, other cells may have a collaborative or regulatory role. Using chimeric models, Rabb and colleagues 130 demonstrated that the production of proinflammatory cytokines, including TNF-a, was attenuated in T-cell-deficient mice, suggesting a role for T cells in triggering inflammation and TNF-a induction during cisplatin nephrotoxicity. It would be interesting to investigate how T cells regulate TNF-a production in renal cells, particularly proximal tubules. In addition to TNF-a, other cytokines produced during the inflammatory response may also contribute to cisplatin nephrotoxicity. Nonetheless, recent work by Faubel et al. 131 did not show a significant role for IL-1b, IL-18, and IL-6 in cisplatin-induced renal injury. Whether other cytokines contribute to cisplatin nephrotoxicity remains to be determined.
RENOPROTECTIVE STRATEGIES AGAINST CISPLATIN NEPHROTOXICITY
During the course of investigation of cisplatin nephrotoxicity, a plethora of pharmacologic, molecular, and genetic approaches have been identified for renoprotection. As summarized in Table 1 , these approaches can be generally classified on the basis of their primary targets: (1) Cisplatin uptake by renal cell. The OCT, hOCT2, is at least partially responsible for transporting cisplatin into renal tubular cells. Pharmacological inhibition of hOCT2 has been shown to have renoprotective effects. However, it is unclear whether hOCT2 inhibition will limit cisplatin uptake by cancer cells and reduce the therapeutic effects in tumors. (2) Cisplatin metabolism and bioactivation. Inhibition of g-glutamyl transpeptidase and cysteine-S-conjugate b-lyase has been shown to decrease cisplatin nephrotoxicity, and, notably, may also potentiate the anticancer effects of cisplatin in tumors.
(3) Cell death pathways. Both in vitro and in vivo studies have shown that directly blocking cell death pathways can ameliorate cisplatin-induced renal cell death and nephrotoxicity. (4) Cell-cycle regulators. p21 is induced during cisplatin nephrotoxicity and protects renal cells from injury and death. Recent work has further suggested that cdk2 inhibitors can protect renal tubular cells and kidneys against cisplatin injury. (5) p53. Pharmacologic, molecular, and genetic blockade of p53 is renoprotective during cisplatin treatment of renal tubular cells as well as whole animals. (6) MAPKs. There is evidence that inhibition of specific MAPKs can partially protect against cisplatin-induced renal tubular cell injury and nephrotoxicity. (7) Oxidative stress. A number of studies conducted in both cell cultures and whole animals have suggested that antioxidants may be used for renoprotection against cisplatin injury, although the results from clinical trials are inconclusive. (8) Inflammation. Overall inhibition of the inflammatory response by IL-10 and specific suppression of TNF-a can protect kidneys during cisplatin treatment. (9) Others. In addition of the above listed approaches, renoprotective effects have also been shown for several pharmacological agents. Particularly, PPAR agonists, fibrate and rosigilitazone, seem to be very effective in protection against cisplatin nephrotoxicity.
PERSPECTIVE ON RENOPROTECTIVE STRATEGIES
As shown in Table 1 and discussed above, numerous approaches have been reported to afford renoprotection during cisplatin treatment. Yet, most of the tests have been conducted only in cultured cells, mice, or rats. As a result, whether these approaches are indeed effective in patients is unknown. To consider clinical use, several important factors have to be kept in mind. (1) Cisplatin has multiple targets in cells and thus blocking a single injurious event may only have partial protective effects in the kidneys. This is clearly shown by the studies conducted thus far. No matter whether inflammation, injury signaling, or cell death pathway is blocked, the protective effects can vary from marginal to impressive levels, but rarely complete. The partial effects by individual approaches suggest that it may be possible and necessary to use several agents together to achieve a clinically meaningful outcome. (2) In consideration of the combinatorial strategies, one has to carefully analyze the specific targets of individual approaches. The best strategy is to take advantages of inhibition at different levels. For example, anti-TNF-a agents that limit inflammation can be used together with approaches that block tubular cell death per se. In addition, MAPK inhibitors and cdk2 inhibitors may also be added to the 'cocktail' treatment. Such combinatorial strategy by simultaneously targeting several injury tiers may significantly improve the renoprotective efficacy. (3) When the focus of renal research is kidney protection, one has to take into consideration the potential effects of renoprotective approaches on the anticancer actions of cisplatin in tumors. After all, cisplatin is a drug for chemotherapy of cancers. If a renoprotective approach diminishes the cancer therapy effects of cisplatin, then practically it would not be immediately useful. Unfortunately, many of the studies focusing on renoprotection were conducted in kidney cells or tumor-free animals. Whether the identified agents or approaches affect cancer therapy effects of cisplatin remains to be examined in tumor-bearing animals. (4) It is expected that many of the documented renoprotective approaches may affect the tumor response to cisplatin. Particularly, inhibition of cell death signaling and pathways that are common to normal and cancer cells would reduce the chemotherapy efficacy of cisplatin in tumors. The use of these approaches would then depend on kidney-specific delivery. (5) Finally, an ideal approach of renoprotection is to protect the kidneys yet enhance the therapeutic effects of cisplatin in cancer cells and tumors. Development of such approaches would rely on the identification of the critical differences between normal kidney cells and malignant cancer cells during cisplatin treatment.
CONCLUSIONS
Research during the last few years has gained significant insights into the signaling pathways that are responsible for cisplatin nephrotoxicity. However, how the various pathways are integrated to induce a remarkable renal pathology remains largely unknown. Along with the mechanistic studies, numerous renoprotective approaches have been documented; nevertheless, the demonstrated protection is mostly partial and combinatorial strategies may offer better protective effects. Importantly, the renoprotective approaches need to be tested in tumor-bearing animals for their potential effects on cisplatin-mediated chemotherapy in cancers. Identification of novel approaches that protect normal tissues including kidneys, without limiting therapeutic effects in cancer cells or tumors, would open new avenues to enhance cisplatin-based cancer therapy.
